Related Experiment Video

Updated: Jun 5, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

Vijay Agarwal1, Michael J Lind, Lynn Cawkwell

  • 1Cancer Biology Proteomics Group, Postgraduate Medical Institute of the University of Hull and Hull York Medical School, Hull, UK.

Cancer Treatment Reviews
|December 25, 2010
PubMed

Insights

Malignant pleural mesothelioma has poor survival, necessitating new treatments. Epidermal growth factor receptor (EGFR) targeted therapies show promise but face resistance, requiring further research for effective mesothelioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Malignant pleural mesothelioma (MPM) exhibits dismal median survival rates.
  • Epidermal growth factor receptor (EGFR) is over-expressed in MPM, presenting a potential therapeutic target.
  • EGFR-targeted therapies are effective in other cancers like non-small cell lung cancer and colorectal cancer.

Purpose of the Study:

  • To review targeted epidermal growth factor receptor (EGFR) treatment strategies for malignant pleural mesothelioma.
  • To explore mechanisms of therapy resistance and the role of predictive biomarkers in MPM.
  • To summarize the current landscape of EGFR-targeted therapies in MPM.

Main Methods:

  • Literature review of clinical trials and preclinical studies.
  • Analysis of EGFR expression patterns in mesothelioma.
  • Investigation of resistance mechanisms to EGFR inhibitors.

Main Results:

  • EGFR tyrosine kinase inhibitors have shown limited efficacy in Phase II trials for mesothelioma.
  • Understanding resistance mechanisms is crucial for improving treatment outcomes.
  • Biomarkers may play a role in predicting response to EGFR-targeted therapies.

Conclusions:

  • Despite EGFR over-expression, direct EGFR inhibition has not yet yielded significant clinical benefit in mesothelioma.
  • Further research into resistance mechanisms and predictive biomarkers is essential.
  • Novel therapeutic strategies targeting EGFR or its downstream pathways are needed for MPM.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...